These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Cleland JG; Dargie HJ; Ball SG; Gillen G; Hodsman GP; Morton JJ; East BW; Robertson I; Ford I; Robertson JI Br Heart J; 1985 Sep; 54(3):305-12. PubMed ID: 2994698 [TBL] [Abstract][Full Text] [Related]
4. Determinants of the initial effects of captopril on blood pressure, glomerular filtration rate, and natriuresis in mild-to-moderate chronic congestive heart failure secondary to coronary artery disease. Motwani JG; Fenwick MK; Morton JJ; Struthers AD Am J Cardiol; 1994 Jun; 73(16):1191-6. PubMed ID: 8203337 [TBL] [Abstract][Full Text] [Related]
5. Captopril in heart failure: a double-blind study of the effects on renal function. Cleland JG; Dargie HJ; Gillen G; Robertson I; East BW; Ball SG; Morton JJ; Robertson JI J Cardiovasc Pharmacol; 1986; 8(4):700-6. PubMed ID: 2427807 [TBL] [Abstract][Full Text] [Related]
6. The use of captopril in the management of cardiac failure. Cleland JG; Dargie HJ; Robertson JI; Ball SG; Hodsman GP Scott Med J; 1984 Apr; 29(2):129-30. PubMed ID: 6099613 [No Abstract] [Full Text] [Related]
13. [Treatment of chronic congestive cardiac insufficiency with an orally active inhibitor of the angiotensin converting enzyme (Captopril)]. Guerrera G; Melina D Minerva Cardioangiol; 1983 Mar; 31(3):93-100. PubMed ID: 6304571 [No Abstract] [Full Text] [Related]
14. Effects of captopril on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive heart failure. Kubo S; Nishioka A; Nishimura H; Kawamura K; Takatsu T Clin Pharmacol Ther; 1984 Oct; 36(4):456-63. PubMed ID: 6206977 [TBL] [Abstract][Full Text] [Related]
15. [A new principle in long-term treatment of essential hypertension: angiotensin-converting enzyme inhibition (author's transl)]. Overlack A; Stumpe KO; Heck I; Krück F Dtsch Med Wochenschr; 1980 Apr; 105(15):505-9. PubMed ID: 6244920 [TBL] [Abstract][Full Text] [Related]
16. Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise. Bayliss J; Canepa-Anson R; Norell MS; Poole-Wilson P; Sutton G Br Heart J; 1986 Mar; 55(3):265-73. PubMed ID: 3513808 [TBL] [Abstract][Full Text] [Related]
17. Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. Packer M; Medina N; Yushak M J Am Coll Cardiol; 1984 Apr; 3(4):1035-43. PubMed ID: 6323565 [TBL] [Abstract][Full Text] [Related]
18. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. MacFadyen RJ; Lees KR; Reid JL Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084 [TBL] [Abstract][Full Text] [Related]
19. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Northridge DB; Currie PF; Newby DE; McMurray JJ; Ford M; Boon NA; Dargie HJ Eur J Heart Fail; 1999 Mar; 1(1):67-72. PubMed ID: 10937982 [TBL] [Abstract][Full Text] [Related]